1. Home
  2. NTWK vs NERV Comparison

NTWK vs NERV Comparison

Compare NTWK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetSol Technologies Inc.

NTWK

NetSol Technologies Inc.

HOLD

Current Price

$2.95

Market Cap

35.5M

Sector

Technology

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$3.93

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTWK
NERV
Founded
1997
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
29.2M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
NTWK
NERV
Price
$2.95
$3.93
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
42.7K
40.1K
Earning Date
02-12-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$66,501,654.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$74.92
N/A
Revenue Growth
7.70
N/A
52 Week Low
$2.14
$1.15
52 Week High
$5.75
$12.46

Technical Indicators

Market Signals
Indicator
NTWK
NERV
Relative Strength Index (RSI) 39.60 47.97
Support Level $2.96 $3.90
Resistance Level $3.13 $4.24
Average True Range (ATR) 0.15 0.27
MACD 0.03 -0.01
Stochastic Oscillator 0.00 30.25

Price Performance

Historical Comparison
NTWK
NERV

About NTWK NetSol Technologies Inc.

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Share on Social Networks: